Merck & Co. announced Tuesday a deal under which Lundbeck will market its atypical antipsychotic drug Sycrest (asenapine) in all markets outside the US, China and Japan.
Under the agreement, Merck will receive an undisclosed payment from Lundbeck in exchange for the rights, as well as product supply fees. The Danish company said it expects to launch the drug in the EU, where it was recently approved as a treatment for patients with moderate-to-severe manic episodes associated with bipolar I disorder, at the start of 2011.
The drug was approved last year in the US, where it is known as Saphris, as a treatment for both schizophrenia and bipolar disorder.
Under the agreement, Merck will receive an undisclosed payment from Lundbeck in exchange for the rights, as well as product supply fees. The Danish company said it expects to launch the drug in the EU, where it was recently approved as a treatment for patients with moderate-to-severe manic episodes associated with bipolar I disorder, at the start of 2011.
The drug was approved last year in the US, where it is known as Saphris, as a treatment for both schizophrenia and bipolar disorder.
Reference Articles
Lundbeck acquires rights to Merck’s bipolar disorder treatment - (Bloomberg)
Lundbeck and Merck sign exclusive commercialisation agreement for Sycrest (asenapine) sublingual tablets in all markets outside of the United States, China and Japan - (Lundbeck)
Merck, Lundbeck in venture on bipolar-mania drug - (MarketWatch)
Merck, Lundbeck sign commercialization deal for Sycrest sublingual tablets - (RTTNews)
**Published in "First Word"
No comments:
Post a Comment